rabi
one
deadli
infecti
diseas
casefat
rate
approach
diseas
establish
contin
apart
antarctica
case
report
africa
asia
thousand
death
record
annual
howev
estim
annual
fi
gure
almost
human
rabi
fatal
probabl
underestim
almost
case
human
rabi
result
bite
infect
dog
therefor
costeff
ectiv
approach
elimin
global
burden
human
rabi
control
canin
rabi
rather
expans
avail
human
prophylaxi
mass
vaccin
campaign
parenter
vaccin
advanc
oral
vaccin
wildlif
allow
elimin
rabi
terrestri
carnivor
sever
countri
worldwid
subsequ
reduct
case
human
rabi
region
advoc
multidisciplinari
one
health
approach
rabi
control
mass
vaccin
dog
control
canin
popul
centuri
rabi
remain
one
fear
import
threat
public
health
untreat
diseas
present
progress
encephalomyel
invari
fatal
caus
neurotrop
virus
genu
lyssaviru
neglect
zoonot
diseas
rabi
present
throughout
much
world
fi
gure
mani
death
human
be
occur
africa
asia
children
younger
year
rabi
regard
underreport
mani
region
due
part
lack
surveil
laboratori
infrastructur
confound
cultur
social
taboo
absenc
accur
data
diseas
incid
turn
tend
reduc
rabi
prioriti
polici
maker
public
health
profession
estim
global
burden
base
model
incid
dog
bite
updat
augment
includ
countryspecifi
c
data
publish
studi
onlin
survey
give
comprehens
global
estim
preliminari
data
suggest
almost
human
death
occur
rabi
global
per
year
attribut
singl
zoonot
diseas
tabl
larg
number
children
among
fatal
mean
rabi
estim
caus
million
disabilityadjust
lifeyear
dali
lost
per
year
annual
econom
cost
us
billion
per
year
model
use
estim
valu
statist
life
predict
econom
impact
rabi
valu
rang
million
per
human
deatha
valu
take
account
postexposur
treatment
livestock
loss
cost
associ
diagnost
test
vaccin
total
annual
global
cost
canin
rabi
alon
estim
order
ten
billion
dollar
dog
princip
vector
human
rabi
respons
human
case
henc
control
rabi
dog
especi
freeroam
stray
dog
fi
rst
prioriti
prevent
human
rabi
diseas
caus
sever
longlast
societ
econom
burden
implic
especi
appar
povertystricken
develop
countri
shortag
resourc
limit
public
health
infrastructur
mani
rabiesendem
countri
preclud
data
collect
analysi
rabi
success
control
dog
popul
throughout
america
rabi
dog
terrestri
wildlif
popul
success
elimin
western
europ
thu
rabi
control
suffi
cient
resourc
alongsid
burden
rabi
terrestri
anim
mani
novel
lyssavirus
caus
clinic
indistinguish
diseas
detect
viru
speci
identifi
ed
detect
bat
includ
speci
antigen
distinct
current
vaccin
strain
aim
seminar
review
avail
inform
rabi
includ
caus
lyssavirus
diseas
transmiss
manag
prevent
also
discuss
new
develop
rabi
research
includ
advanc
epidemiolog
new
lyssaviru
speci
threat
pose
human
health
method
detect
rabi
viru
human
tissu
sampl
advanc
manag
patient
rabi
develop
new
biolog
potenti
replac
human
rabi
immunoglobulin
costeff
ectiv
altern
develop
enhanc
eff
ort
made
toward
overal
goal
human
rabi
elimin
search
pubm
februari
term
rabi
lyssaviru
restrict
date
languag
identifi
ed
articl
rabi
articl
lyssaviru
span
year
sinc
earliest
identifi
ed
public
undertook
specifi
c
search
term
rabi
vaccin
rabi
epidemiolog
rabi
postexposur
prophylaxi
rabi
pathogenesi
articl
rabi
vaccin
articl
rabi
epidemiolog
articl
rabi
postexposur
prophylaxi
articl
rabi
pathogenesi
identifi
ed
review
articl
identifi
ed
gener
specifi
c
search
relev
topic
caus
rabi
rna
virus
belong
genu
lyssaviru
within
famili
rhabdovirida
order
mononegaviral
rabi
viru
rabv
type
speci
respons
case
human
be
anim
howev
case
rabi
involv
human
infect
lyssavirus
also
report
case
seem
lyssavirus
caus
indistinguish
fatal
enceph
human
fatal
case
enceph
caus
lyssaviru
speci
rabv
extrem
rare
howev
surveil
capabl
distinguish
diff
erent
lyssavirus
mani
endem
region
comprehens
intern
committe
taxonomi
virus
delin
lyssaviru
genu
diff
erent
viru
speci
two
tent
viru
speci
base
genet
distanc
antigen
profi
le
geograph
distribut
host
rang
genet
evid
addit
lyssaviru
report
spain
fi
gure
appendix
antigen
genet
profi
le
lyssaviru
genu
allow
segreg
phylogroup
fi
gure
antibodi
rais
experiment
mice
inactiv
viru
one
phylogroup
neutralis
virus
within
phylogroup
other
antibodi
rais
west
caucasian
bat
viru
crossreact
member
two
main
phylogroup
degre
crossneutralis
predict
like
effi
caci
rabvderiv
postexposur
prophylaxi
protect
mediat
vaccin
invers
relat
genet
distanc
infect
viru
isol
rabi
vaccin
strain
pathogenesi
perspect
rabv
experiment
inject
mice
intracrani
deliv
via
peripher
rout
eg
intramuscularli
subcutan
caus
fatal
enceph
contrast
although
lyssavirus
regard
neurotrop
agent
experiment
studi
two
lyssavirus
lago
bat
viru
mokola
viru
mokv
show
diseas
evid
virus
inject
via
peripher
rout
phenomenon
explain
aminoacid
substitut
argli
asp
glycoprotein
ectodomain
generalis
recent
challeng
studi
suggest
pathogen
properti
vari
viru
strain
within
lyssaviru
speci
bat
thought
reservoir
lyssavirus
except
mokv
ikoma
lyssaviru
reservoir
speci
yet
identifi
ed
rabv
detect
extens
bat
speci
throughout
new
world
america
bat
elsewher
wherea
nonrabv
lyssavirus
detect
old
world
bat
speci
africa
europ
asia
furthermor
rabv
present
extens
terrestri
carnivor
speci
across
globe
wherea
remain
lyssavirus
rare
detect
nonfl
ying
speci
mammal
suscept
infect
capabl
act
longterm
reservoir
diseas
rabv
might
evolv
order
chiroptera
ie
bat
later
cross
order
carnivora
ie
terrestri
carnivor
mammal
lyssavirus
envelop
hostderiv
membran
bulletlik
bacilliform
shape
contain
nonseg
neg
sens
rna
genom
appendix
genom
kilobas
pair
length
encod
gene
fi
protein
n
nucleoprotein
p
phosphoprotein
matrix
protein
g
glycoprotein
l
rna
depend
rna
polymeras
n
p
l
protein
viral
rna
form
see
onlin
appendix
figur
rabi
risk
map
data
case
human
rabi
occur
africa
asia
attempt
accur
map
distribut
rabi
risk
incid
show
absenc
quantit
data
irrelev
polit
boundari
control
diseas
anim
reservoir
lowrisk
area
preexposur
immunis
recommend
individu
come
contact
bat
medium
risk
area
preexposur
immunis
recommend
individu
come
contact
bat
wildlif
highrisk
area
preexposur
immunis
recommend
individu
come
contact
domest
anim
dog
rabi
vector
risk
low
risk
medium
risk
high
risk
data
avail
ribonucleoprotein
complex
surround
lipid
envelop
associ
g
protein
g
protein
form
trimer
primari
surfac
antigen
neutralis
antibodi
bind
nucleoprotein
protect
viral
rna
innat
immun
recognit
also
contain
sever
antigen
site
act
major
target
helper
cell
adapt
immun
respons
neg
polar
rna
genom
mean
noninfecti
must
fi
rst
transcrib
produc
complementari
posit
sens
mrna
translat
host
cell
machineri
fi
protein
bind
lyssavirus
host
cell
depend
glycoprotein
bind
one
sever
propos
receptor
facilit
viru
entri
vitro
lyssavirus
seem
abl
infect
divers
rang
cell
line
diff
erent
lineag
although
mechan
entri
variou
cell
express
recognis
receptor
unclear
howev
carbohydr
moieti
phospholipid
sialyl
gangliosid
variou
undefi
ned
protein
associ
membran
thought
act
potenti
bind
port
entri
via
endocyt
pathway
viru
replic
transcript
take
place
neuron
cell
cytoplasm
inclus
term
negri
bodi
previous
thought
dump
ground
excess
viral
protein
lyssaviru
genom
seem
evolv
produc
optimum
level
viral
protein
evidenc
conserv
gene
order
presenc
intergen
region
contain
signal
transcript
initi
termin
polyadenyl
lyssavirus
intergen
region
vari
composit
length
applic
revers
genet
studi
virus
shown
individu
intergen
region
specifi
c
role
gene
express
protein
also
import
role
regul
gene
express
inhibit
transcript
enhanc
replic
although
mechan
regulatori
sequenc
involv
model
transcript
need
studi
viru
bud
host
cell
larg
facilit
protein
rabi
viru
commonli
transmit
bite
rabid
anim
appendix
mechan
enabl
viru
transvers
dermal
barrier
deposit
viru
tissu
initi
infect
fi
gure
host
contribut
onward
transmiss
includ
human
be
term
deadend
host
transmiss
human
be
occur
except
circumst
includ
corneal
organ
transplant
transmiss
rabi
viru
aerosol
exposur
transplant
tissu
organ
rare
report
infect
establish
within
neuron
cell
viru
usurp
host
cell
machineri
reach
cell
bodi
spinal
cord
brainstem
sensori
ganglia
eg
dorsal
root
ganglia
replic
occur
motil
rabv
along
neuron
process
exploit
map
neuron
circuitri
phylogroup
iiiiv
cord
brain
stage
patient
show
clinic
sign
host
detect
viru
intracellularli
occur
retino
acidinduc
gene
pathway
detect
cap
structur
viru
mrna
tolllik
receptor
detect
stimul
earli
interferon
respons
antagonis
viru
phosphoprotein
mechan
interferon
antagon
seem
conserv
mani
lyssavirus
cn
viru
replic
extens
clinic
diseas
develop
notabl
fatal
encephalit
rabi
might
necessarili
accompani
substanti
infl
ammat
featur
could
part
due
genet
infect
viru
variabl
infl
ammatori
respons
also
seen
case
dog
rabi
furthermor
neuronophagia
vari
substanti
neuron
apoptosi
seem
import
role
rabi
enceph
human
be
nonetheless
extens
infect
brain
lead
centrifug
dissemin
viru
neuron
distant
site
throughout
bodi
particular
import
reservoir
speci
spread
viru
peripher
site
releas
viru
oral
caviti
via
salivari
gland
rabi
viru
antigen
stain
tast
bud
also
observ
salivari
gland
innerv
parasympathet
nervou
system
via
submandibular
ganglion
glossopharyng
nerv
sympathet
innerv
via
superior
cervic
ganglion
aff
erent
innerv
ultrastructur
studi
suggest
viru
abl
travel
brain
peripher
site
bud
synapt
adjac
plasma
membran
dendrit
bud
also
occur
albeit
less
often
plasma
membran
perikaryon
detect
viru
particl
engulf
invagin
membran
adjac
axon
terminu
suggest
transneuron
dendroaxon
movement
howev
alongsid
fi
nding
viru
also
report
bud
directli
intercellular
space
along
hypersaliv
aggress
behaviour
often
associ
infect
promot
onward
transmiss
viru
new
host
fi
gure
caus
death
result
infect
rabi
viru
irrefut
establish
overwhelm
viru
replic
nervou
system
lead
mani
system
complic
includ
multiorgan
failur
experiment
studi
show
strong
evid
upregul
interferon
cytokin
chemokin
cn
respons
infect
rabi
viru
transcriptom
studi
shown
upregul
mani
interferoninduc
gene
upregul
support
immunohistolog
demonstr
chemokin
product
neuron
product
drive
infl
ux
immun
cell
cn
particularli
cell
howev
case
rabi
viru
infect
infl
ux
control
infect
host
invari
die
absenc
therapeut
option
mechan
exist
amelior
rabi
viru
replic
viru
reach
brain
evid
immun
respons
detect
viru
enter
cn
fi
gure
viru
avoid
immun
surveil
peripheri
unknown
might
attribut
low
level
replic
earli
infect
activ
immun
suppress
peripheri
two
clinic
form
rabi
diseas
typic
describ
encephalit
furiou
paralyt
dumb
earliest
neurolog
symptom
human
be
usual
pain
paraesthesia
pruritu
site
infect
viral
replic
local
dorsal
root
ganglia
associ
ganglion
prodrom
either
encephalit
paralyt
form
diseas
might
observ
encephalit
rabi
often
present
hypersaliv
period
agit
altern
lucid
observeda
key
featur
socal
furiou
type
rabi
importantli
patient
hypersaliv
diffi
culti
swallow
excess
saliva
produc
video
rabv
nucleic
acid
might
detect
saliva
sampl
taken
stage
hydrophobia
also
often
observ
develop
countri
water
might
ere
suspect
patient
diagnost
purpos
video
hydrophobia
progress
er
water
lead
pharyng
spasm
involuntarili
refus
water
excess
gag
note
video
infect
invari
lead
coma
death
paralyt
form
diseas
diff
er
encephalit
form
muscl
weak
develop
earli
observ
socal
furiou
form
diseas
progress
coma
death
often
take
longer
encephalit
form
bat
rabi
caus
rabv
new
world
wherea
across
old
world
infect
caus
lyssavirus
region
human
infect
bat
lyssavirus
report
rare
howev
true
burden
human
anim
case
caus
lyssavirus
rabv
unknown
caus
lyssaviru
readili
distinguish
standard
diagnost
test
histor
duvenhag
viru
duvv
fi
rst
nonrabi
lyssaviru
associ
human
infect
although
earlier
potenti
infect
european
bat
lyssaviru
type
unconfi
rmed
duvv
fi
rst
report
diagnosi
rabieslik
diseas
individu
south
africa
die
bat
bite
sinc
initi
isol
two
case
duvv
peopl
report
fatal
outcom
african
lyssavirus
mokola
viru
associ
human
fatal
report
nigeria
infect
eurasian
lyssavirus
human
be
also
report
includ
confi
rmed
fatal
infect
irkut
viru
well
infect
australian
bat
lyssaviru
caus
three
human
fatal
although
infect
result
fatal
sever
studi
report
presenc
neutralis
antibodi
peopl
vaccin
fi
nding
suggest
natur
immunis
occur
human
be
infect
rabi
viru
diffi
cult
diagnos
antemortem
although
hydrophobia
highli
suggest
clinic
sign
diseas
pathognomon
rabi
diff
erenti
diagnosi
involv
mani
agent
syndrom
eg
viral
encephalitid
tetanu
listeriosi
poison
coinfect
malaria
lead
misdiagnosi
histor
relianc
detect
accumul
negri
bodi
longer
regard
suitabl
diagnost
assess
low
sensit
altern
laboratorybas
test
develop
conclus
confi
rm
infect
diagnost
test
rabi
viru
anim
need
brain
materi
diagnosi
often
possibl
post
mortem
brain
sampl
readili
taken
breach
skull
sampl
directli
brain
smear
touch
impress
use
detect
viru
antigen
fl
uoresc
antibodi
test
fat
human
anim
sampl
fat
recommend
world
organis
anim
health
oie
case
give
reliabl
result
fresh
specimen
within
hour
avoid
need
expens
fl
uoresc
label
antibodi
fl
uoresc
microscop
histochem
test
direct
rapid
immunohistochem
test
drit
allow
use
lowcost
light
microscopi
develop
drit
detect
rabi
antigen
fresh
brain
impress
within
h
er
addit
advantag
abil
diff
erenti
speci
antemortem
diagnost
test
reliant
widespread
dissemin
viru
nervou
system
antemortem
test
routin
appli
case
anim
infect
antigen
detect
skin
biopsi
use
mean
detect
infect
viru
antigen
detect
nerv
fi
bre
surround
hair
follicl
rabi
viru
nucleic
acid
also
detect
variou
biolog
fl
uid
sampl
eg
saliva
cerebrospin
fl
uid
skin
biopsi
rtpcr
viru
shed
saliva
often
use
antemortem
test
howev
although
saliva
highli
access
sampl
shed
intermitt
ceas
seroconvers
sensit
rtpcr
singl
saliva
sampl
report
low
similar
test
multipl
success
saliva
sampl
nuchal
skin
biopsi
sensit
cessat
viral
shed
seroconvers
requir
nuchal
skin
biopsi
also
taken
possibl
antemortem
diagnost
assess
result
care
consid
combin
rather
reli
individu
diagnost
readout
medic
care
patient
rabi
challeng
physician
especi
region
littl
experi
diseas
complex
treatment
issu
critic
care
use
requir
pend
confi
rmation
laboratori
diagnosi
rabi
aggress
approach
deem
necessari
although
chanc
success
outcom
low
palli
approach
includ
liber
use
sed
analges
need
achiev
comfort
unfortun
eff
ectiv
therapi
exist
rabi
develop
clinic
diseas
clinic
manag
rabi
includ
combin
therapi
rabi
vaccin
immunotherapi
ketamin
ten
peopl
surviv
rabi
includ
one
receiv
preexposur
immunis
eight
receiv
one
dose
postexposur
prophylaxi
onset
rabi
one
individu
neurolog
defi
cit
two
die
within
year
one
individu
surviv
without
postexposur
prophylaxi
administr
aggress
combin
medic
treatment
includ
induct
therapeut
coma
combin
ribavirin
ketamin
amantadin
treatment
approach
dub
milwauke
protocol
gave
initi
promis
novel
treatment
combat
clinic
rabi
howev
attempt
repeat
fi
rst
success
fail
least
subsequ
case
suggest
protocol
ineff
ectiv
excel
medic
care
critic
care
unit
import
specifi
c
therapeut
drug
known
eff
ect
posit
outcom
sever
factor
regard
favour
decis
initi
aggress
therapeut
approach
therapi
dose
rabi
vaccin
onset
ill
young
age
previous
healthi
immunocompet
individu
mild
neurolog
diseas
time
initi
therapi
rabi
due
new
world
bat
rabi
variant
eg
contrast
canin
variant
old
world
bat
variant
earli
detect
neutralis
antirabi
viru
antibodi
serum
cerebrospin
fl
uid
eff
ectiv
therapi
rabi
unlik
develop
futur
trial
error
approach
especi
numer
neuroprotect
drug
studi
fail
show
effi
caci
one
drug
develop
therapi
rabi
much
better
understand
basic
mechan
involv
pathogenesi
diseas
need
knowledg
might
help
develop
eff
ectiv
therapeut
intervent
cool
brain
hypothermia
also
consid
potenti
therapi
earli
rabi
vaccin
base
crude
prepar
anim
neuron
tissu
poorli
immunogen
need
sever
dose
induc
immun
nerv
tissu
vaccin
replac
immunogen
safer
cellculturederiv
vaccin
ccv
despit
offi
cial
recommend
discontinu
use
nerv
tissu
vaccin
countri
still
produc
administ
vaccin
ccv
clinic
trial
enabl
reduct
number
dose
administ
turn
increas
patient
complianc
treatment
well
enabl
altern
rout
administr
adopt
advisori
committe
immun
practic
recommend
singl
preexposur
prophylaxi
prep
regimen
tabl
prep
also
strongli
recommend
travel
endem
countri
wane
antibodi
titr
prep
preexposur
booster
vaccin
dose
also
recom
mend
booster
vaccin
need
administ
accord
vaccin
manufactur
recommend
preexposur
vaccin
given
threedos
schedul
intramuscular
intraderm
inject
day
day
day
fi
rst
dose
individu
risk
exposur
booster
dose
could
administ
depend
individu
mainten
neutralis
antibodi
titr
rel
risk
often
travel
fail
obtain
prep
understand
level
risk
rabi
destin
develop
mass
product
inactiv
ccv
allow
new
approach
rabi
control
fi
rst
time
human
rabi
vaccin
readili
avail
use
exposur
protect
vulner
individu
rather
exclus
employ
postexposur
prophylaxi
although
adult
children
equal
suscept
rabi
prevent
vari
age
rabi
consid
catalogu
paediatr
diseas
endem
region
sinc
annual
death
toll
children
younger
year
prevent
rabi
prep
could
given
children
endem
region
earli
childhood
strategi
rare
lowincom
countri
costbenefi
analysi
adopt
rabi
vaccin
paediatr
regim
conclud
econom
viabil
novel
formul
induc
immun
singl
inocul
need
importantli
licens
rabi
vaccin
good
safeti
record
rare
advers
event
diff
er
accord
age
group
vaccin
present
standard
correl
immun
develop
neutralis
antibodi
memori
recal
respons
poorli
studi
respons
vaccin
despit
consist
wane
antibodi
respons
longterm
followup
studi
vaccin
recipi
wane
might
relat
use
inactiv
viru
current
rabi
vaccin
everi
year
applic
postexposur
prophylaxi
provid
million
treatment
eff
ectiv
countermeasur
rabi
viru
infect
year
rabi
prevent
via
sever
approv
postexposur
prophylaxi
recommend
consist
thorough
woundcleans
prompt
administr
rabi
immun
globulin
rig
togeth
full
cours
rabi
vaccin
tabl
wound
cleans
soap
virucid
antisept
eg
povidon
iodin
copiou
irrig
sutur
unless
absolut
necessari
postexposur
prophylaxi
start
soon
possibl
recognis
exposur
includ
seri
inject
rabi
vaccin
four
diff
erent
postexposur
prophylaxi
vaccin
regimen
current
approv
individu
previous
vaccin
rabi
tabl
three
given
intramuscularli
one
given
intraderm
rig
also
import
compon
postexposur
prophylaxi
inhibit
viral
spread
interv
suffi
cient
immun
develop
respons
vaccin
inject
around
wound
site
ideal
day
exposur
day
initi
dose
vaccin
two
whoapprov
regimen
also
exist
previous
vaccin
individu
tabl
case
rig
given
anim
bite
common
exposur
rabi
infect
appendix
exposur
open
wound
mucos
membran
saliva
nasopharyng
fl
uid
cn
tissu
infect
anim
less
common
irrespect
sourc
exposur
postexposur
prophylaxi
start
promptli
suspect
anim
monitor
period
day
anim
remain
healthi
period
observ
postexposur
prophylaxi
discontinu
suspect
anim
becom
ill
observ
period
full
pep
continu
follow
guidelin
anim
potenti
vector
rabi
exclud
neg
laboratori
examin
brain
fat
anim
test
eg
escap
valuabl
postexposur
prophylaxi
start
unless
inform
local
public
health
offi
cial
suggest
unnecessari
avail
rig
low
rabiesendem
region
even
avail
lack
medic
awar
import
rig
postexposur
prophylaxi
mean
use
often
consid
expens
scarciti
rig
driven
search
altern
prophylact
method
could
made
avail
rabi
endem
area
manufactur
cocktail
select
rabi
monoclon
antibodi
capabl
neutralis
broad
rang
rabv
isol
across
globe
replac
rig
might
promot
use
passiv
immun
rabi
endem
area
need
prepar
undergo
clinic
trial
applic
monoclon
antibodi
principl
plant
biotechnolog
sector
er
promis
direct
novel
prepar
monoclon
antibodi
cocktail
gener
plant
enabl
eas
increas
product
econom
advantag
develop
recombin
rabi
vaccin
propos
applic
revers
genet
gener
rabi
virus
modifi
ed
properti
ideal
gener
robust
memori
respons
vaccin
prepar
could
involv
liveattenu
viru
elicit
strong
memori
respons
although
use
either
preexposur
postexposur
option
requir
extens
develop
progress
area
made
postexposur
treatment
experiment
rabi
anim
rather
postexposur
prophylaxi
manner
licens
vaccin
promin
among
new
prototyp
vaccin
may
licens
futur
treat
rabi
socal
triga
construct
contain
three
copi
glycoprotein
gene
overexpress
glycoprotein
gene
construct
stimul
strong
immun
respons
simultan
seem
attenu
infect
near
futur
virus
probabl
gain
accept
veterinari
vaccin
oral
vaccin
attenu
strain
commonplac
europ
although
often
caus
attenu
deduc
revers
virul
concern
molecular
manipul
vaccin
strain
revers
genet
enabl
mechan
attenu
investig
appli
safe
attenu
rabv
prevent
possibl
revers
virul
high
proport
case
rabi
involv
childhood
fatal
therefor
rabi
consid
import
paediatr
diseas
combin
exist
rabi
human
vaccin
standard
childhood
vaccin
regimen
prioriti
ensur
global
vaccin
rabi
children
live
lowincom
countri
strategi
would
involv
incorpor
rabi
vaccin
exist
childhood
expand
programm
immun
epi
schedul
addit
rabi
vaccin
exist
multival
paediatr
vaccin
part
childhood
epi
schedul
ideal
includ
singledos
vaccin
prefer
noninject
rout
administr
unlik
virus
target
elimin
rabi
never
erad
presenc
lyssavirus
bat
realist
aim
centuri
enhanc
eff
ort
toward
elimin
rabi
dog
result
reduct
human
mortal
goal
alreadi
achiev
sever
region
strateg
approach
programm
aim
elimin
canin
rabi
focu
multidisciplinari
core
dispar
group
includ
repres
public
privat
sector
ie
vaccin
manufactur
polici
maker
scientist
veterinarian
clinician
overal
vision
elimin
human
rabi
collabor
multidisciplinari
initi
often
term
one
health
approach
step
toward
combat
rabi
mass
vaccin
dog
human
manag
dog
popul
financi
support
initi
need
programm
present
paid
charit
foundat
sponsor
fi
nancial
donor
work
partnership
global
institut
alongsid
measur
oie
develop
anim
vaccin
repositori
use
suppli
variou
region
vaccin
food
agricultur
organ
unit
nation
propos
progress
control
pathway
toward
rabi
elimin
fi
nal
stage
pathway
mainten
freedom
rabi
human
anim
support
transgress
commun
district
nation
intern
level
develop
novel
diagnost
techniqu
antemortem
postmortem
diagnost
confi
rmation
endem
region
essenti
enabl
epidemiolog
assess
assess
treatment
option
possibl
pathway
requir
veterinari
servic
control
rabi
dog
propos
oie
sustain
improv
complianc
veterinari
servic
key
compon
perform
vision
strategi
mind
oie
food
agricultur
organis
propos
strategi
elimin
human
rabi
transmit
dog
rabiesendem
countri
recommend
realist
goal
arf
develop
outlin
report
arf
acb
compil
section
integr
review
comment
fi
nal
version
arf
acb
provid
tabl
njlmm
provid
tabl
figur
prepar
acb
appendix
prepar
arf
author
contribut
write
seminar
revis
amend
version
declar
compet
interest
